Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications More
Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications
Voglibose
Voglibose; 83480-29-9; Basen; Glustat; AO-128
Abivog-M2, Advog, Asvogli, Cetapin-V, Cugli, Cugli-MF-XR, Diboset, Glybose, Glyvog, K-Vog, Legli, O-Berry, O-Berry-M, Obiglo-MD, Posmeal, Posmeal-Met, PPG, Ppg-Met, Shambose, Starvog, Starvog-M, Teakol, Tribetrol, V-Bose, V-Bose-M2, V-Glib, V-Glib MD, Vigocil, Vobit, Vobose, Vocarb, Vocarb-MF, Voglase, Vogli, Voglib, Voglicad, Voglicad-M, Vogliday, Voglife, voglifin, Voglimac, Voglimac-MF, Voglinid, Voglinid-M, Voglinid-MD, Voglinorm, Voglinorm-M, Vogliss, Vogliss-M, Voglitab-M
(1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
NA
NA
200-300 mcg tid Oral.
For the treatment of diabetes.
Flatulence; Hepatotoxicity; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT.
May enhance effects of other antidiabetics including insulin.
GI obstruction, hernia; severe ketosis; diabetic coma or pre-coma; Inflammatory bowel disease; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM.
Store below 30°C.
267.2762
C10H21NO7
83480-29-9
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 years; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).
